First Abd Serotec Generated HuCAL Antibodies Distributed As Part Of Clinical Diagnostic Kits for Autoimmune Diseases by Phadia
Jul 21 2008
autoimmune screening platform. AbD Serotec, MorphoSys`s division for research and diagnostic antibodies, receives license fees and will continuously supply Phadia with recombinant antibody material. Further financial details were not disclosed.
Phadia and AbD Serotec began collaborating in September 2005, bringing together Phadia`s expertise in the development, manufacturing and marketing of complete blood test systems and AbD Serotec`s leading recombinant antibody technology HuCAL. AbD Serotec has generated a
series of recombinant antibodies in the IgA, IgM and IgG1 format, which Phadia will implement in its marketed autoimmune tests Varelisa, a classical ELISA microtiter platform, and the fully automated system for the measurement of autoantibodies EliA. The set of recombinant
HuCAL antibodies provided by AbD Serotec act as recombinant control antibodies and replace human serum to standardize autoimmune assays.
Autoimmune diseases include juvenile diabetes, various forms of rheumatism, hepatitis, thyroiditis and a variety of skin diseases. An early diagnosis can improve the treatment options and increase the quality of life for patients significantly.
However, since the early symptoms, especially of systemic autoimmune diseases like rheumatoid disorders, can be very diffuse, several years can pass from the onset of the disease until a correct diagnosis is made. New easy-to-use and cost-effective diagnostic methods could shorten the time-to-diagnosis and subsequent treatment.
âPhadia has a long track record in using advanced techniques such as recombinant gene technology to produce a wide range of precise and reliable diagnostic tests for autoimmune diseases,â commented Stefan Eschbach, Vice President of Phadia. âThe use of recombinant control antibodies was shown to increase the accuracy and reproducibility of diagnostic tests.
AbD Serotec`s ability to generate these highly-specific recombinant antibodies in various formats using the HuCAL technology has been extremely helpful in this regard.â
âToday`s news marks the first market entry of a clinical diagnostic kit comprising a HuCAL antibody,â commented Dr. Simon Moroney, Chief Executive Officer of MorphoSys. âThis development is a significant step forwards for recombinant antibody technology in the diagnostics field, and a major operational milestone for our AbD unit.â
In This Edition Chromatography Articles - Comparing techniques for flow rate measurement in Liquid Chromatography Mass Spectrometry & Spectroscopy Articles - APGC: A Better Future with...
View all digital editions
Feb 29 2024 Dhaka, Bangladesh
Feb 29 2024 Kathmandu, Nepal
Mar 03 2024 Bethesda, MA, USA
Mar 04 2024 Guanghzou, China
Mar 05 2024 Guangzhou, China